Results 251 to 260 of about 1,602,505 (289)
Some of the next articles are maybe not open access.
Live-attenuated chikungunya virus vaccine
CellAlthough Chikungunya fever does not a have a high fatality rate (
Lisa F P, Ng, Laurent, Rénia
openaire +2 more sources
Live Attenuated Vaccines for Pandemic Influenza
2009In this chapter, we will review the development of and clinical experience with the currently licensed seasonal live attenuated influenza vaccines (LAIV) and preclinical studies of H5, H7, and H9 live attenuated pandemic influenza vaccine candidates. Vectored vaccine approaches will not be reviewed in this chapter.
Grace L, Chen, Kanta, Subbarao
openaire +2 more sources
Live attenuated vaccines for human use
Current Opinion in Biotechnology, 1992Live attenuated vaccines have been successfully used for the prevention of a number of viral and bacterial diseases. Several vaccine strains have been utilized recently as expression vectors for cloned heterologous antigens. Through the use of recombinant DNA technology, candidate vaccine strains and vector systems have been developed and are ...
openaire +2 more sources
Live attenuated influenza vaccine for children
Drug and Therapeutics Bulletin, 2017For many years, the UK seasonal influenza vaccination programme has been offered to people at higher risk from the complications of influenza infection, including those aged over 65 years and anyone aged over 6 months who is in a clinical risk group.1 In 2012, the Joint Committee on Vaccination and Immunisation (JCVI) recommended extending seasonal ...
openaire +2 more sources
Generation of a Live Attenuated Influenza A Vaccine by Proteolysis Targeting
Nature Biotechnology, 2022Chengxin Zhang, Longlong Si, Haiqing Bai
exaly
A Single-Dose Live-Attenuated YF17D-Vectored SARS-CoV-2 Vaccine Candidate
Nature, 2021Koen Van Laere +2 more
exaly
Studies with Live Attenuated Influenza Vaccines
American Journal of Clinical Pathology, 1979G, Florent, F, André
openaire +2 more sources
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Cell Host and Microbe, 2020Raul Andino +2 more
exaly
A Live-Attenuated SARS-CoV-2 Vaccine Candidate With Accessory Protein Deletions
Nature Communications, 2022Pei-Yong Shi +2 more
exaly

